Skip to main content
Evidence Snapshot

Tissue factor pathway inhibitor

CHEMBL3713062 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:55:54Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3713062
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tissue factor pathway inhibitor as ChEMBL target CHEMBL3713062, mapped to UniProt P10646. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tissue factor pathway inhibitor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3713062
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P10646
Tissue factor pathway inhibitor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Tissue factor pathway inhibitor matters

As of 2026-09-13

Tissue factor pathway inhibitor is reviewed as Tissue factor pathway inhibitor (UniProt P10646); Tissue factor pathway inhibitor shows approved-linked disease relevance led by hemophilia A. 4 more disease programs remain visible in the same review block.; 3 linked drugs keep this evidence frame grounded.; the current evidence base includes 0 approved drugs, 2010 compounds, and 133 assays, with lead potency reaching pChEMBL 10.3.

Disease context
hemophilia A

Tissue factor pathway inhibitor shows approved-linked disease relevance led by hemophilia A. 4 more disease programs remain visible in the same review block. 3 linked drugs keep the rationale reviewable. 4 additional disease programs remain visible in the same card. Linked drugs include BAY-1093884, CONCIZUMAB, MARSTACIMAB.

Start review with hemophilia A because it currently carries approved-linked support. Linked drugs include BAY-1093884, CONCIZUMAB, MARSTACIMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 3 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 0 approved drugs, 2010 compounds, and 133 assays for this target. The dominant activity type is IC50. CHEMBL4545581 is the current potency anchor at pChEMBL 10.3.

Use CHEMBL4545581 as the tractability anchor when discussing potency (pChEMBL 10.3).

Activity source · ChEMBL 36 via Core Engine
pChEMBL 10.3
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Tissue factor pathway inhibitor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P10646, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why hemophilia A is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2010
Total Compounds
133
Total Assays
0
Approved Drugs
IC50: 3924.0, KI: 6.0, EC50: 1169.0, KD: 8.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4545581
 10.3 Kd —
No preferred name
CHEMBL4543933
 10.2 EC50 —
No preferred name
CHEMBL3894172
 9.5 Kd —
No preferred name
CHEMBL4473203
 9.5 IC50 —
No preferred name
CHEMBL4447126
 9.2 IC50 —
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T19:55:54Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3713062